Covering the current state of equity markets, COVID-19 outlook and portfolio positioning (5mins).
VRX Silica identified the silica sand shortage in the Asia-Pacific region as a unique opportunity for Western Australia. The shortage, which is predicted to worsen with dwindling local supplies and increasing demand, has caused an increase in price.
The Asia-Pacific region accounts for 47% of global demand for silica sand and is predicted to grow by 6.1% to 138 million metric tonnes in 2019 according to Freedonia Group.
Western Australia is well positioned to meet this rising demand in Asia-Pacific markets for silica sand.
Founded in 2007, we are a Sydney-based regenerative medicine company developing a portfolio of novel cell-based therapies targeting unmet medical needs in humans, with an initial focus on osteoarthritis (OA), neuropathic pain and dermatology. All of the products in our pipeline are underpinned by proprietary stem cell technologies.
Our stem cell technologies use mesenchymal stem cells (MSCs) from adipose tissue. MSCs are responsible for promoting the body’s natural healing, by reducing inflammation, promoting tissue repair and reducing scarring. MSCs from adipose tissue are found in much greater numbers than other tissue types (e.g. bone marrow, blood) and are readily available throughout the whole body. Our stem cell technology platform allows for scalable production of allogeneic cell products for a wide range of therapeutic indications, optimising the licensing prospects for each technology platform. We have developed technology and protocols for the production of cell secretions from MSCs for the treatment of inflammatory skin conditions (Sygenus).
Our substantial intellectual property (IP) covers a broad range of clinical indications across our product portfolio, creating value for partnering with larger companies for global commercialisation.
Nuheara is an innovative audio wearables company that has developed proprietary and multi-functional intelligent hearing technology that augments a person’s hearing and facilitates cable free connection to smart devices. We are based in Perth, Australia and have offices in San Francisco and New York, USA. Nuheara was the first wearables technology company to be listed on the ASX (Australian Stock Exchange).
In 2016, we released our revolutionary wireless earbuds, IQbuds, which allows customers to augment their hearing according to their personal hearing preferences and connect hands free with their voice-enabled smart devices. Our mission is to improve people’s lives by allowing them to seamlessly listen, communicate, and connect to their physical and digital world.
Novonix Limited, formerly Graphitecorp Limited, is an Australia-based company. The Company is engaged in developing and Supplying of materials, equipment and services for the global lithium-ion battery industry. Novonix improves batteries for electric vehicles, phones, laptops, cordless equipment and renewable energy storage.
The company through its subsidiary NOVONIX Battery Testing Services Inc.,develops and sells the battery cell test equipment, which are used by battery makers, researchers and equipment manufacturers. The Company through its PUREgraphite joint venture with COULOMETRICS, develops and manufactures battery anode materials in the United States. PUREgraphite anode materials can be used in electric vehicle applications.
OptiScan (ASX:OIL) is a global leader in the development of endomicroscopic imaging technologies for medical, translational and pre-clinical applications. Our technology enables real-time, in vivo imaging at the cellular level in human and animal tissue and is used by leading research institutions and hospitals in North America, Europe, Asia and Australia.
OptiScan’s FIVE2 (ViewnVivo) system is the latest hand-held, confocal endomicroscope, especially designed for translational and pre-clinical research, enabling imaging in 3D at the cellular level. The system’s flexibility facilitates research in applications including live imaging of dynamic processes, assessment of dysplastic and diseased tissue, tumour margin mapping, imaging of molecular disease markers, blood flow and clots, barrier function, infection and pharmacokinetics across tissue types and organ systems. This research leads to enhanced knowledge as well as the potential for clinical and veterinary applications.